$AVDL
AVADEL PHARMACEUTICALS PLC Stock $avdl

$avdl Overview Financials Valuation SEC Filings Company Website

2020 Q4 Form 10-K Financial Statement

#000101247721000004 Filed on March 09, 2021

Income Statement

Concept	2020 Q4	2020	2019 Q4
Revenue	$0.00	$22.33M	$11.00M
YoY Change	-100.0%	-62.28%	-47.42%
Cost Of Revenue	$0.00	$5.742M	$2.410M
YoY Change	-100.0%	-52.64%	-43.82%
Gross Profit	$0.00	$16.59M	$8.580M
YoY Change	-100.0%	-64.77%	-48.41%
Gross Profit Margin		74.29%	78.0%
Selling, General & Admin	$8.970M	$32.41M	$7.660M
YoY Change	17.1%	7.36%	-66.98%
% of Gross Profit		195.3%	89.28%
Research & Development	$5.290M	$20.44M	$7.760M
YoY Change	-31.83%	-37.9%	27.42%
% of Gross Profit		123.2%	90.44%
Depreciation & Amortization	$390.0K	$287.0K	$800.0K
YoY Change	-51.25%	-37.47%	-55.56%
% of Gross Profit		1.73%	9.32%
Operating Expenses	$14.26M	$52.85M	$15.63M
YoY Change	-8.77%	-16.25%	-49.43%
Operating Profit	-$14.26M	$5.815M	-$7.050M
YoY Change	102.27%	-124.12%	-50.63%
Interest Expense	-$3.310M	$12.99M	-$4.670M
YoY Change	-29.12%	4.09%	35.76%
% of Operating Profit		223.46%
Other Income/Expense, Net	$3.440M	-$435.0K	$120.0K
YoY Change	2766.67%	15.08%	-74.47%
Pretax Income	-$14.13M	-$5.082M	-$11.74M
YoY Change	20.36%	-86.83%	-85.02%
Income Tax	-$2.850M	-$12.11M	-$9.000M
% Of Pretax Income
Net Earnings	-$11.28M	$7.028M	-$2.740M
YoY Change	311.68%	-121.15%	-95.71%
Net Earnings / Revenue		31.47%	-24.91%
Basic Earnings Per Share		$0.13
Diluted Earnings Per Share	-$193.2K	$0.13	-$73.13K
COMMON SHARES
Basic Shares Outstanding	58.27M shares	53.00M shares	37.45M shares
Diluted Shares Outstanding		54.94M shares

Balance Sheet

Concept	2020 Q4	2020	2019 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$222.9M	$222.9M	$64.20M
YoY Change	247.2%	247.2%	-37.85%
Cash & Equivalents	$71.72M	$71.70M	$9.774M
Short-Term Investments	$151.2M	$151.2M	$54.40M
Other Short-Term Assets	$798.0K	$1.500M	$107.0K
YoY Change	645.79%	-31.82%	-52.44%
Inventory	$0.00	$0.00	$3.570M
Prepaid Expenses	$1.018M		$2.116M
Receivables	$0.00	$16.80M	$8.281M
Other Receivables	$22.30M	$22.30M	$3.700M
Total Short-Term Assets	$263.5M	$263.5M	$82.38M
YoY Change	219.8%	219.78%	-34.02%
LONG-TERM ASSETS
Property, Plant & Equipment	$359.0K	$3.000M	$544.0K
YoY Change	-34.01%	-28.57%	-71.53%
Goodwill	$16.84M		$18.49M
YoY Change	-8.95%		0.0%
Intangibles	$0.00		$813.0K
YoY Change	-100.0%		-50.09%
Long-Term Investments	$0.00	$0.00	$1.500M
YoY Change	-100.0%	-100.0%	0.0%
Other Assets	$24.94M	$24.90M	$39.27M
YoY Change	-36.5%	-34.13%	8.65%
Total Long-Term Assets	$48.18M	$48.10M	$69.06M
YoY Change	-30.23%	-30.29%	5.51%
TOTAL ASSETS
Total Short-Term Assets	$263.5M	$263.5M	$82.38M
Total Long-Term Assets	$48.18M	$48.10M	$69.06M
Total Assets	$311.6M	$311.6M	$151.4M
YoY Change	105.79%	105.81%	-20.42%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.934M	$2.900M	$6.100M
YoY Change	-51.9%	-52.46%	74.14%
Accrued Expenses	$6.501M	$5.900M	$19.81M
YoY Change	-67.18%	-57.86%	-8.69%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00		$0.00
YoY Change			-100.0%
Total Short-Term Liabilities	$15.11M	$15.10M	$35.98M
YoY Change	-58.01%	-58.06%	-6.25%
LONG-TERM LIABILITIES
Long-Term Debt	$128.2M	$128.2M	$121.7M
YoY Change	5.36%	5.34%	5.14%
Other Long-Term Liabilities	$4.212M	$6.100M	$8.873M
YoY Change	-52.53%	-73.48%	-36.63%
Total Long-Term Liabilities	$132.4M	$134.3M	$130.6M
YoY Change	1.43%	-7.19%	0.63%
TOTAL LIABILITIES
Total Short-Term Liabilities	$15.11M	$15.10M	$35.98M
Total Long-Term Liabilities	$132.4M	$134.3M	$130.6M
Total Liabilities	$149.4M	$149.4M	$180.6M
YoY Change	-17.31%	-17.28%	-3.67%
SHAREHOLDERS EQUITY
Retained Earnings	-$384.2M		-$391.2M
YoY Change	-1.8%		9.28%
Common Stock	$567.5M		$434.8M
YoY Change	30.51%		0.15%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$0.00		$50.00M
YoY Change	-100.0%		0.0%
Treasury Stock Shares	0.000 shares		5.407M shares
Shareholders Equity	$162.3M	$162.3M	-$29.20M
YoY Change
Total Liabilities & Shareholders Equity	$311.6M	$311.6M	$151.4M
YoY Change	105.79%	105.81%	-20.42%

Cashflow Statement

Concept	2020 Q4	2020	2019 Q4
OPERATING ACTIVITIES
Net Income	-$11.28M	$7.028M	-$2.740M
YoY Change	311.68%	-121.15%	-95.71%
Depreciation, Depletion And Amortization	$390.0K	$287.0K	$800.0K
YoY Change	-51.25%	-37.47%	-55.56%
Cash From Operating Activities	-$19.12M	-$48.73M	-$8.260M
YoY Change	131.48%	27.16%	-66.33%
INVESTING ACTIVITIES
Capital Expenditures	-$70.00K	$98.00K	$0.00
YoY Change		237.93%	-100.0%
Acquisitions
YoY Change
Other Investing Activities	$7.310M	-$69.62M	$5.170M
YoY Change	41.39%	-279.66%	-68.13%
Cash From Investing Activities	$7.240M	-$69.72M	$5.170M
YoY Change	40.04%	-280.05%	-68.11%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	180.0K	$179.7M	-40.00K
YoY Change	-550.0%	-665592.59%	-50.0%
NET CHANGE
Cash From Operating Activities	-19.12M	-$48.73M	-8.260M
Cash From Investing Activities	7.240M	-$69.72M	5.170M
Cash From Financing Activities	180.0K	$179.7M	-40.00K
Net Change In Cash	-11.70M	$61.95M	-3.130M
YoY Change	273.8%	13696.88%	-62.74%
FREE CASH FLOW
Cash From Operating Activities	-$19.12M	-$48.73M	-$8.260M
Capital Expenditures	-$70.00K	$98.00K	$0.00
Free Cash Flow	-$19.05M	-$48.83M	-$8.260M
YoY Change	130.63%	27.32%	-66.31%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2020	dei	Entity Central Index Key EntityCentralIndexKey	0001012477
CY2020	dei	Amendment Flag AmendmentFlag	false
CY2020	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2020	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
CY2020	dei	Document Type DocumentType	10-K
CY2020	dei	Document Annual Report DocumentAnnualReport	true
CY2020	dei	Document Period End Date DocumentPeriodEndDate	2020-12-31
CY2020	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2020	dei	Document Transition Report DocumentTransitionReport	false
CY2020	dei	Entity File Number EntityFileNumber	000-28508
CY2020	dei	Entity Registrant Name EntityRegistrantName	AVADEL PHARMACEUTICALS PLC
CY2020	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	L2
CY2020	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	98-1341933
CY2020	dei	Entity Address Address Line1 EntityAddressAddressLine1	10 Earlsfort Terrace
CY2020	dei	Entity Address City Or Town EntityAddressCityOrTown	Dublin 2
CY2020	dei	Entity Address Country EntityAddressCountry	IE
CY2020	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	D02 T380
CY2020	dei	City Area Code CityAreaCode	1
CY2020	dei	Local Phone Number LocalPhoneNumber	485-1200
CY2020	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2020	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2020	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2020	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2020	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2020	dei	Entity Small Business EntitySmallBusiness	false
CY2020	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2020	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2020	dei	Entity Shell Company EntityShellCompany	false
CY2020Q2	dei	Entity Public Float EntityPublicFloat	466741289	USD
CY2021Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	58465151	shares
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	22334000	USD
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	59215000	USD
CY2018	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	103269000	USD
CY2020	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	5742000	USD
CY2019	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	12125000	USD
CY2018	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	17516000	USD
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	20442000	USD
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	32917000	USD
CY2018	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	39329000	USD
CY2020	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	32405000	USD
CY2019	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	30183000	USD
CY2018	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	100359000	USD
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	406000	USD
CY2019	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	816000	USD
CY2018	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	6619000	USD
CY2020	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	3327000	USD
CY2019	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	845000	USD
CY2018	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	-22731000	USD
CY2020	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	45760000	USD
CY2019	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	0	USD
CY2018	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	0	USD
CY2020	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	USD
CY2019	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	USD
CY2018	us-gaap	Asset Impairment Charges AssetImpairmentCharges	66087000	USD
CY2020	avdl	Restructuring Costs Net RestructuringCostsNet	-43000	USD
CY2019	avdl	Restructuring Costs Net RestructuringCostsNet	6441000	USD
CY2018	avdl	Restructuring Costs Net RestructuringCostsNet	1016000	USD
CY2020	us-gaap	Costs And Expenses CostsAndExpenses	16519000	USD
CY2019	us-gaap	Costs And Expenses CostsAndExpenses	83327000	USD
CY2018	us-gaap	Costs And Expenses CostsAndExpenses	208195000	USD
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	5815000	USD
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-24112000	USD
CY2018	us-gaap	Operating Income Loss OperatingIncomeLoss	-104926000	USD
CY2020	us-gaap	Investment Income Net InvestmentIncomeNet	-832000	USD
CY2019	us-gaap	Investment Income Net InvestmentIncomeNet	1069000	USD
CY2018	us-gaap	Investment Income Net InvestmentIncomeNet	452000	USD
CY2020	us-gaap	Interest Expense Debt InterestExpenseDebt	12994000	USD
CY2019	us-gaap	Interest Expense Debt InterestExpenseDebt	12483000	USD
CY2018	us-gaap	Interest Expense Debt InterestExpenseDebt	10622000	USD
CY2020	us-gaap	Deconsolidation Revaluation Of Retained Investment Gain Or Loss Amount DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount	3364000	USD
CY2019	us-gaap	Deconsolidation Revaluation Of Retained Investment Gain Or Loss Amount DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount	0	USD
CY2018	us-gaap	Deconsolidation Revaluation Of Retained Investment Gain Or Loss Amount DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount	0	USD
CY2020	us-gaap	Deconsolidation Gain Or Loss Amount DeconsolidationGainOrLossAmount	0	USD
CY2019	us-gaap	Deconsolidation Gain Or Loss Amount DeconsolidationGainOrLossAmount	-2678000	USD
CY2018	us-gaap	Deconsolidation Gain Or Loss Amount DeconsolidationGainOrLossAmount	0	USD
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-435000	USD
CY2019	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-378000	USD
CY2018	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1899000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-5082000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-38582000	USD
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-113197000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-12110000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-5356000	USD
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-17893000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	7028000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-33226000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-95304000	USD
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.13
CY2019	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.89
CY2018	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.55
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.13
CY2019	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.89
CY2018	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.55
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	52996000	shares
CY2019	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	37403000	shares
CY2018	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	37325000	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	54941000	shares
CY2019	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	37403000	shares
CY2018	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	37325000	shares
CY2020	us-gaap	Net Income Loss NetIncomeLoss	7028000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-33226000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-95304000	USD
CY2020	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	1111000	USD
CY2019	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-117000	USD
CY2018	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-419000	USD
CY2020	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	-202000	USD
CY2019	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	-43000	USD
CY2018	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	-18000	USD
CY2020	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	644000	USD
CY2019	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	727000	USD
CY2018	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	269000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	1755000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	610000	USD
CY2018	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-150000	USD
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	8783000	USD
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-32616000	USD
CY2018	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-95454000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	71722000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9774000	USD
CY2020Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	149680000	USD
CY2019Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	54384000	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	0	USD
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	8281000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	0	USD
CY2019Q4	us-gaap	Inventory Net InventoryNet	3570000	USD
CY2020Q4	avdl	Research And Development Tax Credit Receivable Current ResearchAndDevelopmentTaxCreditReceivableCurrent	3326000	USD
CY2019Q4	avdl	Research And Development Tax Credit Receivable Current ResearchAndDevelopmentTaxCreditReceivableCurrent	2107000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	38726000	USD
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4264000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	263454000	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	82380000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	359000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	544000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2604000	USD
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3612000	USD
CY2020Q4	us-gaap	Goodwill Goodwill	16836000	USD
CY2019Q4	us-gaap	Goodwill Goodwill	18491000	USD
CY2020Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	0	USD
CY2019Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	813000	USD
CY2020Q4	avdl	Research And Development Tax Credit Receivable Non Current ResearchAndDevelopmentTaxCreditReceivableNonCurrent	3445000	USD
CY2019Q4	avdl	Research And Development Tax Credit Receivable Non Current ResearchAndDevelopmentTaxCreditReceivableNonCurrent	6322000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	24939000	USD
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	39274000	USD
CY2020Q4	us-gaap	Assets Assets	311637000	USD
CY2019Q4	us-gaap	Assets Assets	151436000	USD
CY2020Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	0	USD
CY2019Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	5554000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	474000	USD
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	645000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2934000	USD
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	6100000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6501000	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	19810000	USD
CY2020Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	5200000	USD
CY2019Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	3875000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	15109000	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	35984000	USD
CY2020Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	128210000	USD
CY2019Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	121686000	USD
CY2020Q4	us-gaap	Due To Related Parties Noncurrent DueToRelatedPartiesNoncurrent	0	USD
CY2019Q4	us-gaap	Due To Related Parties Noncurrent DueToRelatedPartiesNoncurrent	11773000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1840000	USD
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2319000	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	4212000	USD
CY2019Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	8873000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	149371000	USD
CY2019Q4	us-gaap	Liabilities Liabilities	180635000	USD
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2019Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000	shares
CY2019Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000	shares
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	488000	shares
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	488000	shares
CY2019Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2019Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	5000	USD
CY2019Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	58396000	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	58396000	shares
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	42927000	shares
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	37520000	shares
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	583000	USD
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	429000	USD
CY2020Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	0	shares
CY2019Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	5407000	shares
CY2020Q4	us-gaap	Treasury Stock Value TreasuryStockValue	0	USD
CY2019Q4	us-gaap	Treasury Stock Value TreasuryStockValue	49998000	USD
CY2020Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	566916000	USD
CY2019Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	434391000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-384187000	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-391215000	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-21051000	USD
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-22806000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	162266000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	-29199000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	311637000	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	151436000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	85580000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-95304000	USD
CY2018	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-150000	USD
CY2018	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	535000	USD
CY2018	avdl	Stock Issued During Period Value Expiration Of Warrants StockIssuedDuringPeriodValueExpirationOfWarrants	2911000	USD
CY2020	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	60570000	USD
CY2018	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	2167000	USD
CY2018	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	0	USD
CY2018	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	127000	USD
CY2018	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	7852000	USD
CY2018	us-gaap	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt	26699000	USD
CY2018	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	27637000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	2780000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-33226000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	610000	USD
CY2019	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	0	USD
CY2019	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	118000	USD
CY2019	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	519000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	-29199000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	7028000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	1755000	USD
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	2045000	USD
CY2020	avdl	Stock Issued During Period Value Public Offering StockIssuedDuringPeriodValuePublicOffering	116924000	USD
CY2020	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	0	USD
CY2020	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	144000	USD
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2999000	USD
CY2020	us-gaap	Treasury Stock Retired Cost Method Amount TreasuryStockRetiredCostMethodAmount	0	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	162266000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	7028000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-33226000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-95304000	USD
CY2020	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1690000	USD
CY2019	us-gaap	Depreciation And Amortization DepreciationAndAmortization	2486000	USD
CY2018	us-gaap	Depreciation And Amortization DepreciationAndAmortization	7430000	USD
CY2020	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	USD
CY2019	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	USD
CY2018	us-gaap	Asset Impairment Charges AssetImpairmentCharges	66087000	USD
CY2020	avdl	Acquisition Related Contingent Consideration Remeasurement AcquisitionRelatedContingentConsiderationRemeasurement	3327000	USD
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	519000	USD
CY2019	avdl	Acquisition Related Contingent Consideration Remeasurement AcquisitionRelatedContingentConsiderationRemeasurement	845000	USD
CY2018	avdl	Acquisition Related Contingent Consideration Remeasurement AcquisitionRelatedContingentConsiderationRemeasurement	-22731000	USD
CY2020	avdl	Financing Related Contingent Consideration Remeasurement FinancingRelatedContingentConsiderationRemeasurement	435000	USD
CY2019	avdl	Financing Related Contingent Consideration Remeasurement FinancingRelatedContingentConsiderationRemeasurement	378000	USD
CY2018	avdl	Financing Related Contingent Consideration Remeasurement FinancingRelatedContingentConsiderationRemeasurement	-1899000	USD
CY2020	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	6524000	USD
CY2019	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	5995000	USD
CY2018	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	4830000	USD
CY2020	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	7431000	USD
CY2019	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	6334000	USD
CY2018	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	19152000	USD
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	2999000	USD
CY2018	us-gaap	Share Based Compensation ShareBasedCompensation	7852000	USD
CY2020	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	45760000	USD
CY2019	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	0	USD
CY2018	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	0	USD
CY2020	avdl	Noncash Gain Loss Deconsolidation Of Subsidiary NoncashGainLossDeconsolidationOfSubsidiary	0	USD
CY2019	avdl	Increase Decrease In Research And Development Tax Credit Receivable IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable	1014000	USD
CY2019	avdl	Noncash Gain Loss Deconsolidation Of Subsidiary NoncashGainLossDeconsolidationOfSubsidiary	-1750000	USD
CY2018	avdl	Noncash Gain Loss Deconsolidation Of Subsidiary NoncashGainLossDeconsolidationOfSubsidiary	0	USD
CY2020	us-gaap	Deconsolidation Revaluation Of Retained Investment Gain Or Loss Amount DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount	3364000	USD
CY2019	us-gaap	Deconsolidation Revaluation Of Retained Investment Gain Or Loss Amount DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount	0	USD
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1863000	USD
CY2018	avdl	Increase Decrease In Research And Development Tax Credit Receivable IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable	2545000	USD
CY2018	us-gaap	Deconsolidation Revaluation Of Retained Investment Gain Or Loss Amount DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount	0	USD
CY2020	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	142000	USD
CY2019	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	-254000	USD
CY2018	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	4188000	USD
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-8281000	USD
CY2019	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-2471000	USD
CY2018	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-3452000	USD
CY2020	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1352000	USD
CY2019	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-1155000	USD
CY2018	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-711000	USD
CY2019	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1187000	USD
CY2018	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-3577000	USD
CY2020	avdl	Increase Decrease In Research And Development Tax Credit Receivable IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable	-2213000	USD
CY2019	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	4641000	USD
CY2020	us-gaap	Payments For Royalties PaymentsForRoyalties	866000	USD
CY2019	us-gaap	Payments For Royalties PaymentsForRoyalties	1748000	USD
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-2788000	USD
CY2018	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-2032000	USD
CY2020	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	0	USD
CY2019	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-114000	USD
CY2018	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-1892000	USD
CY2020	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-13226000	USD
CY2019	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	357000	USD
CY2018	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-10640000	USD
CY2020	avdl	Earn Out Payment In Excess Of Acquisition Date Fair Value EarnOutPaymentInExcessOfAcquisitionDateFairValue	5323000	USD
CY2019	avdl	Earn Out Payment In Excess Of Acquisition Date Fair Value EarnOutPaymentInExcessOfAcquisitionDateFairValue	10988000	USD
CY2018	avdl	Earn Out Payment In Excess Of Acquisition Date Fair Value EarnOutPaymentInExcessOfAcquisitionDateFairValue	19468000	USD
CY2018	us-gaap	Payments For Royalties PaymentsForRoyalties	2838000	USD
CY2020	us-gaap	Increase Decrease In Other Noncurrent Assets And Liabilities Net IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet	3126000	USD
CY2019	us-gaap	Increase Decrease In Other Noncurrent Assets And Liabilities Net IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet	4057000	USD
CY2018	us-gaap	Increase Decrease In Other Noncurrent Assets And Liabilities Net IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet	2342000	USD
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-48734000	USD
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-38325000	USD
CY2018	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-82716000	USD
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	98000	USD
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	29000	USD
CY2018	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	178000	USD
CY2020	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	USD
CY2019	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	154000	USD
CY2018	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	USD
CY2020	us-gaap	Proceeds From Divestiture Of Businesses ProceedsFromDivestitureOfBusinesses	25500000	USD
CY2019	us-gaap	Proceeds From Divestiture Of Businesses ProceedsFromDivestitureOfBusinesses	0	USD
CY2018	us-gaap	Proceeds From Divestiture Of Businesses ProceedsFromDivestitureOfBusinesses	0	USD
CY2020	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0	USD
CY2019	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0	USD
CY2018	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	20000000	USD
CY2020	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	36284000	USD
CY2019	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	63246000	USD
CY2018	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	359507000	USD
CY2020	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	131407000	USD
CY2019	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	24648000	USD
CY2018	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	376310000	USD
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-69721000	USD
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	38723000	USD
CY2018	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-36981000	USD
CY2020	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	USD
CY2019	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	USD
CY2018	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	143750000	USD
CY2020	us-gaap	Repayments Of Other Long Term Debt RepaymentsOfOtherLongTermDebt	0	USD
CY2019	us-gaap	Repayments Of Other Long Term Debt RepaymentsOfOtherLongTermDebt	0	USD
CY2018	us-gaap	Repayments Of Other Long Term Debt RepaymentsOfOtherLongTermDebt	6190000	USD
CY2020	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities	0	USD
CY2019	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities	0	USD
CY2018	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities	2911000	USD
CY2020	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	60570000	USD
CY2019	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	0	USD
CY2018	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	0	USD
CY2020	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	116924000	USD
CY2019	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	0	USD
CY2018	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	0	USD
CY2020	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	2189000	USD
CY2019	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	118000	USD
CY2018	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	577000	USD
CY2020	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	0	USD
CY2019	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	0	USD
CY2018	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	27637000	USD
CY2020	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	0	USD
CY2019	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-145000	USD
CY2018	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-752000	USD
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	179683000	USD
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-27000	USD
CY2018	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	112659000	USD
CY2020	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	720000	USD
CY2019	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	78000	USD
CY2018	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-201000	USD
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	61948000	USD
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	449000	USD
CY2018	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-7239000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9774000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9325000	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	16564000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	71722000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9774000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9325000	USD
CY2020	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	-1701000	USD
CY2019	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	140000	USD
CY2018	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	776000	USD
CY2020	us-gaap	Interest Paid Net InterestPaidNet	6469000	USD
CY2019	us-gaap	Interest Paid Net InterestPaidNet	6469000	USD
CY2018	us-gaap	Interest Paid Net InterestPaidNet	3359000	USD
CY2020	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	Reclassifications<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain reclassifications are made to prior year amounts whenever necessary to conform with the current year presentation. Certain adjustments have been made to the Consolidated Statements of Cash Flows for the fiscal year ended December 31, 2020 and balances within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 16: Other Assets and Liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the year ended December 31, 2019 to condense line items of the same nature into a single line. This change does not affect previously reported net cash flows used in operating activities in the Consolidated Statements of Cash Flows. We made certain reclassifications within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 10: Goodwill and Intangible Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to the gross value and total accumulated amortization balances of the Vazculep intangible asset as of December 31, 2019. We made certain adjustments to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 24: Company Operations by Product, Customer, and Geographic Area</span> to include comparable information for customers that became significant for the year ended December 31, 2020.
CY2019	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	USD
CY2020	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	USD
CY2020	us-gaap	Use Of Estimates UseOfEstimates	Use of Estimates. The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, including marketable securities and contingent liabilities at the date of the consolidated financial statements and the reported amounts of sales and expenses during the periods presented. These estimates and assumptions are based on the best information available to management at the balance sheet dates and depending on the nature of the estimate can require significant judgments. Changes to these estimates and judgments can have and have had a material impact on our consolidated statements of income (loss) and balance sheets. Actual results could differ from those estimates under different assumptions or conditions.
CY2020Q3	us-gaap	Bankruptcy Claims Amount Paid To Settle Claims BankruptcyClaimsAmountPaidToSettleClaims	800000	USD
CY2020Q4	us-gaap	Deconsolidation Revaluation Of Retained Investment Gain Or Loss Amount DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount	3364000	USD
CY2019	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	1228000	USD
CY2020Q4	us-gaap	Capitalized Contract Cost Net CapitalizedContractCostNet	0	USD
CY2019Q4	us-gaap	Capitalized Contract Cost Net CapitalizedContractCostNet	0	USD
CY2018Q4	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	1600000	USD
CY2020Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	0	USD
CY2019Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	0	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	147903000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	1815000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	38000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	149680000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	53238000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	1151000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	5000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	54384000	USD
CY2020	avdl	Marketable Securities Realized Gain MarketableSecuritiesRealizedGain	474000	USD
CY2019	avdl	Marketable Securities Realized Gain MarketableSecuritiesRealizedGain	483000	USD
CY2018	avdl	Marketable Securities Realized Gain MarketableSecuritiesRealizedGain	317000	USD
CY2020	avdl	Marketable Securities Realized Loss MarketableSecuritiesRealizedLoss	912000	USD
CY2019	avdl	Marketable Securities Realized Loss MarketableSecuritiesRealizedLoss	151000	USD
CY2018	avdl	Marketable Securities Realized Loss MarketableSecuritiesRealizedLoss	565000	USD
CY2020Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	0	USD
CY2019Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	914000	USD
CY2020Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	0	USD
CY2019Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	3020000	USD
CY2020Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	0	USD
CY2019Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	550000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	0	USD
CY2019Q4	us-gaap	Inventory Net InventoryNet	3570000	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1384000	USD
CY2019Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1014000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	359000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	544000	USD
CY2020	us-gaap	Depreciation Depreciation	287000	USD
CY2019	us-gaap	Depreciation Depreciation	459000	USD
CY2018	us-gaap	Depreciation Depreciation	811000	USD
CY2020Q4	us-gaap	Goodwill Gross GoodwillGross	16836000	USD
CY2020Q4	us-gaap	Goodwill Impaired Accumulated Impairment Loss GoodwillImpairedAccumulatedImpairmentLoss	0	USD
CY2020Q4	us-gaap	Goodwill Goodwill	16836000	USD
CY2019Q4	us-gaap	Goodwill Gross GoodwillGross	18491000	USD
CY2019Q4	us-gaap	Goodwill Impaired Accumulated Impairment Loss GoodwillImpairedAccumulatedImpairmentLoss	0	USD
CY2019Q4	us-gaap	Goodwill Goodwill	18491000	USD
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	406000	USD
CY2019	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	816000	USD
CY2018	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	6619000	USD
CY2019	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	USD
CY2020	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2604000	USD
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	2314000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	474000	USD
CY2020	us-gaap	Operating Lease Cost OperatingLeaseCost	1133000	USD
CY2019	us-gaap	Operating Lease Cost OperatingLeaseCost	1515000	USD
CY2020	us-gaap	Sublease Income SubleaseIncome	336000	USD
CY2019	us-gaap	Sublease Income SubleaseIncome	276000	USD
CY2020	us-gaap	Lease Cost LeaseCost	797000	USD
CY2019	us-gaap	Lease Cost LeaseCost	1239000	USD
CY2020	us-gaap	Operating Lease Payments OperatingLeasePayments	769000	USD
CY2019	us-gaap	Operating Lease Payments OperatingLeasePayments	1480000	USD
CY2020Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y3M18D
CY2020Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.053
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	578000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	590000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	602000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	614000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	206000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	0	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	2590000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	276000	USD
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	2314000	USD
CY2020Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	0	USD
CY2019Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	0	USD
CY2020Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	128210000	USD
CY2019Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	121686000	USD
CY2018Q1	avdl	American Depository Shares Conversion Ratio AmericanDepositorySharesConversionRatio	92.6956	Rate
CY2019Q4	us-gaap	Business Combination Liabilities Arising From Contingencies Amount Recognized BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized	17327000	USD
CY2020	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	6189000	USD
CY2020	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	3327000	USD
CY2020	avdl	Business Combination Financing Related Costs BusinessCombinationFinancingRelatedCosts	435000	USD
CY2020	us-gaap	Discontinued Operation Gain Loss On Disposal Of Discontinued Operation Net Of Tax DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax	14900000	USD
CY2020Q4	us-gaap	Business Combination Liabilities Arising From Contingencies Amount Recognized BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized	0	USD
CY2019Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	5554000	USD
CY2020Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	0	USD
CY2019Q4	us-gaap	Due To Related Parties Noncurrent DueToRelatedPartiesNoncurrent	11773000	USD
CY2020Q4	us-gaap	Due To Related Parties Noncurrent DueToRelatedPartiesNoncurrent	0	USD
CY2013Q4	avdl	Cash Consideration Received On Royalty Agreement CashConsiderationReceivedOnRoyaltyAgreement	2200000	USD
CY2013Q4	avdl	Percentage Of Royalty Payable On Net Sales PercentageOfRoyaltyPayableOnNetSales	0.00834
CY2017Q4	us-gaap	Business Combination Liabilities Arising From Contingencies Amount Recognized BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized	98925000	USD
CY2018	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	22951000	USD
CY2018	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	-24630000	USD
CY2018	us-gaap	Payments For Repurchase Of Warrants PaymentsForRepurchaseOfWarrants	2167000	USD
CY2018	us-gaap	Disposal Group Not Discontinued Operation Gain Loss On Disposal DisposalGroupNotDiscontinuedOperationGainLossOnDisposal	-20337000	USD
CY2018Q4	us-gaap	Business Combination Liabilities Arising From Contingencies Amount Recognized BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized	28840000	USD
CY2019	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	12736000	USD
CY2019	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	1223000	USD
CY2019Q4	us-gaap	Business Combination Liabilities Arising From Contingencies Amount Recognized BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized	17327000	USD
CY2020	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	6189000	USD
CY2020	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	3762000	USD
CY2020	us-gaap	Discontinued Operation Gain Loss On Disposal Of Discontinued Operation Net Of Tax DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax	14900000	USD
CY2020Q4	us-gaap	Business Combination Liabilities Arising From Contingencies Amount Recognized BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized	0	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-5082000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-38582000	USD
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-113197000	USD
CY2020	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	-12810000	USD
CY2019	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2018	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2020	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	20000	USD
CY2019	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	97000	USD
CY2018	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	330000	USD
CY2020	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	-12790000	USD
CY2019	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	97000	USD
CY2018	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	330000	USD
CY2020	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0	USD
CY2019	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-1256000	USD
CY2018	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	680000	USD
CY2019	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-4093000	USD
CY2018	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-19503000	USD
CY2020	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	USD
CY2019	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-104000	USD
CY2018	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	1280000	USD
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	680000	USD
CY2019	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-5453000	USD
CY2018	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-18223000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-12110000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-5356000	USD
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-17893000	USD
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.125
CY2019	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.125
CY2018	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.125
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.345
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	-0.194
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.032
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.080
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	-0.003
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	0.040
CY2020	avdl	Effective Income Tax Rate Reconciliation Intercompany Asset Transfer Percent EffectiveIncomeTaxRateReconciliationIntercompanyAssetTransferPercent	0
CY2019	avdl	Effective Income Tax Rate Reconciliation Intercompany Asset Transfer Percent EffectiveIncomeTaxRateReconciliationIntercompanyAssetTransferPercent	0.212
CY2018	avdl	Effective Income Tax Rate Reconciliation Intercompany Asset Transfer Percent EffectiveIncomeTaxRateReconciliationIntercompanyAssetTransferPercent	0
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.833
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.191
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.053
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.209
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.027
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.013
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	1.835
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Tax Contingencies EffectiveIncomeTaxRateReconciliationTaxContingencies	0.054
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Tax Contingencies EffectiveIncomeTaxRateReconciliationTaxContingencies	0.007
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Tax Contingencies EffectiveIncomeTaxRateReconciliationTaxContingencies	-0.013
CY2020	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.004
CY2019	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0
CY2018	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.003
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	1.795
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	-0.002
CY2020	avdl	Effective Income Tax Rate Reconciliation Nondeductible Expense Interest Expense Percent EffectiveIncomeTaxRateReconciliationNondeductibleExpenseInterestExpensePercent	-0.340
CY2019	avdl	Effective Income Tax Rate Reconciliation Nondeductible Expense Interest Expense Percent EffectiveIncomeTaxRateReconciliationNondeductibleExpenseInterestExpensePercent	-0.025
CY2018	avdl	Effective Income Tax Rate Reconciliation Nondeductible Expense Interest Expense Percent EffectiveIncomeTaxRateReconciliationNondeductibleExpenseInterestExpensePercent	-0.011
CY2019	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.139
CY2018	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.157
CY2020	avdl	Effective Income Tax Rate Reconciliation Percent Orphan Drug And Research And Development Tax Credit EffectiveIncomeTaxRateReconciliationPercentOrphanDrugAndResearchAndDevelopmentTaxCredit	0.550
CY2019	avdl	Effective Income Tax Rate Reconciliation Percent Orphan Drug And Research And Development Tax Credit EffectiveIncomeTaxRateReconciliationPercentOrphanDrugAndResearchAndDevelopmentTaxCredit	0
CY2018	avdl	Effective Income Tax Rate Reconciliation Percent Orphan Drug And Research And Development Tax Credit EffectiveIncomeTaxRateReconciliationPercentOrphanDrugAndResearchAndDevelopmentTaxCredit	0
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	-0.051
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	0.009
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	0.007
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	2.383
CY2020	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-636000	USD
CY2019	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-4823000	USD
CY2018	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-14149000	USD
CY2020	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	1755000	USD
CY2019	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	-1218000	USD
CY2018	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	-9039000	USD
CY2020	us-gaap	Income Tax Reconciliation Nondeductible Expense Other IncomeTaxReconciliationNondeductibleExpenseOther	988000	USD
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-17893000	USD
CY2019	us-gaap	Income Tax Reconciliation Nondeductible Expense Other IncomeTaxReconciliationNondeductibleExpenseOther	121000	USD
CY2018	us-gaap	Income Tax Reconciliation Nondeductible Expense Other IncomeTaxReconciliationNondeductibleExpenseOther	-4559000	USD
CY2020	avdl	Effective Income Tax Rate Reconciliation Intercompany Asset Transfer Amount EffectiveIncomeTaxRateReconciliationIntercompanyAssetTransferAmount	0	USD
CY2019	avdl	Effective Income Tax Rate Reconciliation Intercompany Asset Transfer Amount EffectiveIncomeTaxRateReconciliationIntercompanyAssetTransferAmount	-8190000	USD
CY2018	avdl	Effective Income Tax Rate Reconciliation Intercompany Asset Transfer Amount EffectiveIncomeTaxRateReconciliationIntercompanyAssetTransferAmount	0	USD
CY2020	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	4231000	USD
CY2019	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	7379000	USD
CY2018	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	5998000	USD
CY2020	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	1060000	USD
CY2019	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	1039000	USD
CY2018	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	1499000	USD
CY2020	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-9328000	USD
CY2019	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	0	USD
CY2018	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	0	USD
CY2020	us-gaap	Income Tax Reconciliation Tax Contingencies IncomeTaxReconciliationTaxContingencies	-274000	USD
CY2019	us-gaap	Income Tax Reconciliation Tax Contingencies IncomeTaxReconciliationTaxContingencies	-261000	USD
CY2018	us-gaap	Income Tax Reconciliation Tax Contingencies IncomeTaxReconciliationTaxContingencies	1440000	USD
CY2020	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	20000	USD
CY2019	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-7000	USD
CY2018	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	299000	USD
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Tax Cuts And Jobs Act Of2017 Amount EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Amount	-9124000	USD
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Tax Cuts And Jobs Act Of2017 Amount EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Amount	0	USD
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Tax Cuts And Jobs Act Of2017 Amount EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Amount	274000	USD
CY2020	avdl	Effective Income Tax Rate Reconciliation Nondeductible Expense Interest Expense Amount EffectiveIncomeTaxRateReconciliationNondeductibleExpenseInterestExpenseAmount	1728000	USD
CY2019	avdl	Effective Income Tax Rate Reconciliation Nondeductible Expense Interest Expense Amount EffectiveIncomeTaxRateReconciliationNondeductibleExpenseInterestExpenseAmount	982000	USD
CY2018	avdl	Effective Income Tax Rate Reconciliation Nondeductible Expense Interest Expense Amount EffectiveIncomeTaxRateReconciliationNondeductibleExpenseInterestExpenseAmount	1269000	USD
CY2020	avdl	Effective Income Tax Rate Reconciliation Amount Orphan Drug And Research And Development Tax Credit EffectiveIncomeTaxRateReconciliationAmountOrphanDrugAndResearchAndDevelopmentTaxCredit	2793000	USD
CY2019	avdl	Effective Income Tax Rate Reconciliation Amount Orphan Drug And Research And Development Tax Credit EffectiveIncomeTaxRateReconciliationAmountOrphanDrugAndResearchAndDevelopmentTaxCredit	0	USD
CY2018	avdl	Effective Income Tax Rate Reconciliation Amount Orphan Drug And Research And Development Tax Credit EffectiveIncomeTaxRateReconciliationAmountOrphanDrugAndResearchAndDevelopmentTaxCredit	0	USD
CY2020	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	263000	USD
CY2019	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	-378000	USD
CY2018	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	-925000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-12110000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-5356000	USD
CY2020	us-gaap	Increase Decrease In Income Taxes IncreaseDecreaseInIncomeTaxes	6754000	USD
CY2019	us-gaap	Increase Decrease In Income Taxes IncreaseDecreaseInIncomeTaxes	-12537000	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	6465000	USD
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	5315000	USD
CY2017Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	3954000	USD
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	0	USD
CY2019	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	0	USD
CY2018	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	1087000	USD
CY2020	us-gaap	Unrecognized Tax Benefits Period Increase Decrease UnrecognizedTaxBenefitsPeriodIncreaseDecrease	0	USD
CY2019	us-gaap	Unrecognized Tax Benefits Period Increase Decrease UnrecognizedTaxBenefitsPeriodIncreaseDecrease	2416000	USD
CY2018	us-gaap	Unrecognized Tax Benefits Period Increase Decrease UnrecognizedTaxBenefitsPeriodIncreaseDecrease	274000	USD
CY2020	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	0	USD
CY2019	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	1266000	USD
CY2018	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	0	USD
CY2020	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities	3322000	USD
CY2019	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities	0	USD
CY2018	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities	0	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	3143000	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	6465000	USD
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	5315000	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	2483000	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	3806000	USD
CY2018Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	4597000	USD
CY2020	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	203000	USD
CY2019	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	555000	USD
CY2018	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	725000	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	1475000	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	1612000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	31302000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	30275000	USD
CY2020Q4	avdl	Deferred Tax Assets Amortizationof Intangible Assets DeferredTaxAssetsAmortizationofIntangibleAssets	3701000	USD
CY2019Q4	avdl	Deferred Tax Assets Amortizationof Intangible Assets DeferredTaxAssetsAmortizationofIntangibleAssets	11602000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	2626000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	3577000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	0	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	53000	USD
CY2020Q4	avdl	Deferred Tax Assets Fair Value Contingent Consideration DeferredTaxAssetsFairValueContingentConsideration	0	USD
CY2019Q4	avdl	Deferred Tax Assets Fair Value Contingent Consideration DeferredTaxAssetsFairValueContingentConsideration	264000	USD
CY2020Q4	avdl	Deferred Tax Assets Tax Credit Carryforwards Orphan Drug And Research DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrugAndResearch	2793000	USD
CY2019Q4	avdl	Deferred Tax Assets Tax Credit Carryforwards Orphan Drug And Research DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrugAndResearch	0	USD
CY2020Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	423000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	901000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	40845000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	46672000	USD
CY2020Q4	avdl	Deferred Tax Liabilities Amortization DeferredTaxLiabilitiesAmortization	0	USD
CY2019Q4	avdl	Deferred Tax Liabilities Amortization DeferredTaxLiabilitiesAmortization	172000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	75000	USD
CY2019Q4	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	35000	USD
CY2019Q4	avdl	Guarantee Noncurrent GuaranteeNoncurrent	1367000	USD
CY2020Q4	avdl	Operating Lease Right Of Use Asset Contract Manufacturing Noncurrent OperatingLeaseRightOfUseAssetContractManufacturingNoncurrent	5201000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	890000	USD
CY2019Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	0	USD
CY2020Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	965000	USD
CY2019Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	207000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	21624000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	17038000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	18256000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	29427000	USD
CY2020	avdl	Effective Income Tax Rate Reconciliation Amount Orphan Drug And Research And Development Tax Credit EffectiveIncomeTaxRateReconciliationAmountOrphanDrugAndResearchAndDevelopmentTaxCredit	2793000	USD
CY2020	us-gaap	Undistributed Earnings UndistributedEarnings	3725000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	6771000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	8429000	USD
CY2020	avdl	Effective Income Tax Rate Reconciliation Amount Orphan Drug And Research And Development Tax Credit EffectiveIncomeTaxRateReconciliationAmountOrphanDrugAndResearchAndDevelopmentTaxCredit	2793000	USD
CY2020Q4	avdl	Coronavirus Aid Relief And Economic Security Act Cares Act Changein Tax Rate Deferred Tax Liability Income Tax Benefit CoronavirusAidReliefAndEconomicSecurityActCARESActChangeinTaxRateDeferredTaxLiabilityIncomeTaxBenefit	9124000	USD
CY2020	avdl	Cares Act Proceeds From Income Tax Refunds CARESActProceedsFromIncomeTaxRefunds	3351000	USD
CY2020	avdl	Cares Act Cash Refund Claims CARESActCashRefundClaims	18753000	USD
CY2018	us-gaap	Tax Cuts And Jobs Act Of2017 Income Tax Expense Benefit TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit	274000	USD
CY2019	us-gaap	Defined Contribution Plan Increase Decrease Cost DefinedContributionPlanIncreaseDecreaseCost	1000000	USD
CY2020Q4	us-gaap	Value Added Tax Receivable Current ValueAddedTaxReceivableCurrent	341000	USD
CY2019Q4	us-gaap	Value Added Tax Receivable Current ValueAddedTaxReceivableCurrent	1051000	USD
CY2020Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1018000	USD
CY2019Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	2116000	USD
CY2020Q4	avdl	Advance To Suppliers And Other Current Assets AdvanceToSuppliersAndOtherCurrentAssets	318000	USD
CY2019Q4	avdl	Advance To Suppliers And Other Current Assets AdvanceToSuppliersAndOtherCurrentAssets	454000	USD
CY2020Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	18615000	USD
CY2019Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	536000	USD
CY2020Q4	avdl	Short Term Note Receivable ShortTermNoteReceivable	16500000	USD
CY2019Q4	avdl	Short Term Note Receivable ShortTermNoteReceivable	0	USD
CY2020Q4	us-gaap	Short Term Investments ShortTermInvestments	1477000	USD
CY2019Q4	us-gaap	Short Term Investments ShortTermInvestments	0	USD
CY2020Q4	us-gaap	Other Assets Current OtherAssetsCurrent	457000	USD
CY2019Q4	us-gaap	Other Assets Current OtherAssetsCurrent	107000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	38726000	USD
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4264000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	18256000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	29427000	USD
CY2020Q4	us-gaap	Long Term Investments LongTermInvestments	0	USD
CY2019Q4	us-gaap	Long Term Investments LongTermInvestments	1477000	USD
CY2020Q4	avdl	Guarantee Noncurrent GuaranteeNoncurrent	1050000	USD
CY2019Q4	avdl	Operating Lease Right Of Use Asset Contract Manufacturing Noncurrent OperatingLeaseRightOfUseAssetContractManufacturingNoncurrent	6428000	USD
CY2020Q4	avdl	Other Noncurrent Receivables OtherNoncurrentReceivables	432000	USD
CY2019Q4	avdl	Other Noncurrent Receivables OtherNoncurrentReceivables	575000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	24939000	USD
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	39274000	USD
CY2020Q4	us-gaap	Workers Compensation Liability Current WorkersCompensationLiabilityCurrent	1697000	USD
CY2019Q4	us-gaap	Workers Compensation Liability Current WorkersCompensationLiabilityCurrent	3944000	USD
CY2020Q4	us-gaap	Restructuring Reserve Current RestructuringReserveCurrent	520000	USD
CY2019Q4	us-gaap	Restructuring Reserve Current RestructuringReserveCurrent	2949000	USD
CY2020Q4	avdl	Accrued Trade Discounts And Rebates AccruedTradeDiscountsAndRebates	1030000	USD
CY2019Q4	avdl	Accrued Trade Discounts And Rebates AccruedTradeDiscountsAndRebates	6470000	USD
CY2020Q4	avdl	Accrued Expensefor Paymentof Intangible Assets Current AccruedExpenseforPaymentofIntangibleAssetsCurrent	473000	USD
CY2019Q4	avdl	Accrued Expensefor Paymentof Intangible Assets Current AccruedExpenseforPaymentofIntangibleAssetsCurrent	2833000	USD
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2781000	USD
CY2019Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	3614000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6501000	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	19810000	USD
CY2020Q4	avdl	Accrued Interest Current AccruedInterestCurrent	2695000	USD
CY2019Q4	avdl	Accrued Interest Current AccruedInterestCurrent	2695000	USD
CY2020Q4	us-gaap	Due To Affiliate Current DueToAffiliateCurrent	2026000	USD
CY2019Q4	us-gaap	Due To Affiliate Current DueToAffiliateCurrent	0	USD
CY2020Q4	avdl	Other Guarantor Obligations Current Carrying Value OtherGuarantorObligationsCurrentCarryingValue	319000	USD
CY2019Q4	avdl	Other Guarantor Obligations Current Carrying Value OtherGuarantorObligationsCurrentCarryingValue	455000	USD
CY2020Q4	avdl	Other Liabilities Miscellaneous Current OtherLiabilitiesMiscellaneousCurrent	160000	USD
CY2019Q4	avdl	Other Liabilities Miscellaneous Current OtherLiabilitiesMiscellaneousCurrent	725000	USD
CY2020Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	5200000	USD
CY2019Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	3875000	USD
CY2020Q4	us-gaap	Customer Refund Liability Noncurrent CustomerRefundLiabilityNoncurrent	0	USD
CY2019Q4	us-gaap	Customer Refund Liability Noncurrent CustomerRefundLiabilityNoncurrent	981000	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	3143000	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	6465000	USD
CY2020Q4	us-gaap	Guaranty Liabilities GuarantyLiabilities	1053000	USD
CY2019Q4	us-gaap	Guaranty Liabilities GuarantyLiabilities	1372000	USD
CY2020Q4	us-gaap	Other Long Term Debt OtherLongTermDebt	16000	USD
CY2019Q4	us-gaap	Other Long Term Debt OtherLongTermDebt	55000	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	4212000	USD
CY2019Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	8873000	USD
CY2020Q4	us-gaap	Purchase Obligation PurchaseObligation	4000000	USD
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	58396000	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	58396000	shares
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000	shares
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	488000	shares
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	488000	shares
CY2020Q1	avdl	Maximum Aggregate Offering Priceof Securities Under Shelf Registration MaximumAggregateOfferingPriceofSecuritiesUnderShelfRegistration	250000	USD
CY2020Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2020Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2020Q1	avdl	Maximum Aggregate Offering Priceof American Depositary Shares Under Shelf Registration MaximumAggregateOfferingPriceofAmericanDepositarySharesUnderShelfRegistration	50000	USD
CY2020Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	428000	USD
CY2020Q1	avdl	Maximum Threshold Percentage For Trigger Of Convertible Preferred Stock MaximumThresholdPercentageForTriggerOfConvertiblePreferredStock	0.0999
CY2020Q3	us-gaap	Treasury Stock Shares Retired TreasuryStockSharesRetired	5407000	shares
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2999000	USD
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	519000	USD
CY2018	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7852000	USD
CY2020Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	12322000	USD
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P3Y4M24D
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5121000	shares
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	1841000	USD
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.51
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2551000	shares
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	6.90
CY2020	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	403000	shares
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	5.08
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	566000	shares
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	3.24
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	805000	shares
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	13.37
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5898000	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.02
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P7Y11M15D
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	7115000	USD
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	2172000	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	9.48
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y6M29D
CY2020Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	1841000	USD
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	572000	USD
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	0	USD
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	4.63
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.24
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	3.60
CY2020Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight	1	shares
CY2020	us-gaap	Net Income Loss NetIncomeLoss	7028000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-33226000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-95304000	USD
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	52996000	shares
CY2019	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	37403000	shares
CY2018	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	37325000	shares
CY2020	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	1945000	shares
CY2019	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
CY2018	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	54941000	shares
CY2019	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	37403000	shares
CY2018	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	37325000	shares
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.13
CY2019	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.89
CY2018	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.55
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.13
CY2019	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.89
CY2018	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.55
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	14915000	shares
CY2019	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	16740000	shares
CY2018	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	17529000	shares
CY2020	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	-202000	USD
CY2019	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	-43000	USD
CY2018	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	-18000	USD
CY2020	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2020	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	22334000	USD
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	59215000	USD
CY2018	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	103269000	USD
CY2019Q4	us-gaap	Noncurrent Assets NoncurrentAssets	29694000	USD
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	22334000	USD
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	59215000	USD
CY2018	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	103269000	USD
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	22334000	USD
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	59215000	USD
CY2018	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	103269000	USD
CY2020Q4	us-gaap	Noncurrent Assets NoncurrentAssets	26482000	USD
CY2018Q4	us-gaap	Noncurrent Assets NoncurrentAssets	35154000	USD

Files In Submission

Name	View Source	Status
0001012477-21-000004-index-headers.html	Edgar Link	pending
0001012477-21-000004-index.html	Edgar Link	pending
0001012477-21-000004.txt	Edgar Link	pending
0001012477-21-000004-xbrl.zip	Edgar Link	pending
a123120ex-101.htm	Edgar Link	pending
a123120ex-101001.jpg	Edgar Link	pending
a123120ex-101002.jpg	Edgar Link	pending
a123120ex-101003.jpg	Edgar Link	pending
a123120ex-101004.jpg	Edgar Link	pending
a123120ex-101005.jpg	Edgar Link	pending
a123120ex-101006.jpg	Edgar Link	pending
a123120ex-101007.jpg	Edgar Link	pending
a123120ex-101008.jpg	Edgar Link	pending
a123120ex-101009.jpg	Edgar Link	pending
a123120ex-101010.jpg	Edgar Link	pending
a123120ex-101011.jpg	Edgar Link	pending
a123120ex-101012.jpg	Edgar Link	pending
a123120ex-101013.jpg	Edgar Link	pending
a123120ex-101014.jpg	Edgar Link	pending
a123120ex-101015.jpg	Edgar Link	pending
a123120ex-101016.jpg	Edgar Link	pending
a123120ex-101017.jpg	Edgar Link	pending
a123120ex-101018.jpg	Edgar Link	pending
a123120ex-101019.jpg	Edgar Link	pending
a123120ex-101020.jpg	Edgar Link	pending
a123120ex-101021.jpg	Edgar Link	pending
a123120ex-101022.jpg	Edgar Link	pending
a123120ex-101023.jpg	Edgar Link	pending
a123120ex-101024.jpg	Edgar Link	pending
a123120ex-101025.jpg	Edgar Link	pending
a123120ex-101026.jpg	Edgar Link	pending
a123120ex-1018.htm	Edgar Link	pending
a123120ex-1019.htm	Edgar Link	pending
a123120ex-102.htm	Edgar Link	pending
a123120ex-102001.jpg	Edgar Link	pending
a123120ex-102002.jpg	Edgar Link	pending
a123120ex-102003.jpg	Edgar Link	pending
a123120ex-102004.jpg	Edgar Link	pending
a123120ex-102005.jpg	Edgar Link	pending
a123120ex-102006.jpg	Edgar Link	pending
a123120ex-102007.jpg	Edgar Link	pending
a123120ex-102008.jpg	Edgar Link	pending
a123120ex-102009.jpg	Edgar Link	pending
a123120ex-102010.jpg	Edgar Link	pending
a123120ex-102011.jpg	Edgar Link	pending
a123120ex-102012.jpg	Edgar Link	pending
a123120ex-102013.jpg	Edgar Link	pending
a123120ex-102014.jpg	Edgar Link	pending
a123120ex-102015.jpg	Edgar Link	pending
a123120ex-102016.jpg	Edgar Link	pending
a123120ex-102017.jpg	Edgar Link	pending
a123120ex-102018.jpg	Edgar Link	pending
a123120ex-102019.jpg	Edgar Link	pending
a123120ex-102020.jpg	Edgar Link	pending
a123120ex-102021.jpg	Edgar Link	pending
a123120ex-102022.jpg	Edgar Link	pending
a123120ex-102023.jpg	Edgar Link	pending
a123120ex-102024.jpg	Edgar Link	pending
a123120ex-102025.jpg	Edgar Link	pending
a123120ex-102026.jpg	Edgar Link	pending
a123120ex-102027.jpg	Edgar Link	pending
a123120ex-102028.jpg	Edgar Link	pending
a123120ex-102029.jpg	Edgar Link	pending
a123120ex-102030.jpg	Edgar Link	pending
a123120ex-102031.jpg	Edgar Link	pending
a123120ex-102032.jpg	Edgar Link	pending
a123120ex-102033.jpg	Edgar Link	pending
a123120ex-102034.jpg	Edgar Link	pending
a123120ex-102035.jpg	Edgar Link	pending
a123120ex-102036.jpg	Edgar Link	pending
a123120ex-102037.jpg	Edgar Link	pending
a123120ex-102038.jpg	Edgar Link	pending
a123120ex-102039.jpg	Edgar Link	pending
a123120ex-102040.jpg	Edgar Link	pending
a123120ex-102041.jpg	Edgar Link	pending
a123120ex-102042.jpg	Edgar Link	pending
a123120ex-102043.jpg	Edgar Link	pending
a123120ex-102044.jpg	Edgar Link	pending
a123120ex-102045.jpg	Edgar Link	pending
a123120ex-102046.jpg	Edgar Link	pending
a123120ex-102047.jpg	Edgar Link	pending
a123120ex-102048.jpg	Edgar Link	pending
a123120ex-102049.jpg	Edgar Link	pending
a123120ex-102050.jpg	Edgar Link	pending
a123120ex-102051.jpg	Edgar Link	pending
a123120ex-102052.jpg	Edgar Link	pending
a123120ex-102053.jpg	Edgar Link	pending
a123120ex-102054.jpg	Edgar Link	pending
a123120ex-102055.jpg	Edgar Link	pending
a123120ex-102056.jpg	Edgar Link	pending
a123120ex-102057.jpg	Edgar Link	pending
a123120ex-102058.jpg	Edgar Link	pending
a123120ex-102059.jpg	Edgar Link	pending
a123120ex-102060.jpg	Edgar Link	pending
a123120ex-102061.jpg	Edgar Link	pending
a123120ex-102062.jpg	Edgar Link	pending
a123120ex-102063.jpg	Edgar Link	pending
a123120ex-102064.jpg	Edgar Link	pending
a123120ex-102065.jpg	Edgar Link	pending
a123120ex-102066.jpg	Edgar Link	pending
a123120ex-102067.jpg	Edgar Link	pending
a123120ex-102068.jpg	Edgar Link	pending
a123120ex-102069.jpg	Edgar Link	pending
a123120ex-102070.jpg	Edgar Link	pending
a123120ex-102071.jpg	Edgar Link	pending
a123120ex-102072.jpg	Edgar Link	pending
a123120ex-102073.jpg	Edgar Link	pending
a123120ex-102074.jpg	Edgar Link	pending
a123120ex-102075.jpg	Edgar Link	pending
a123120ex-102076.jpg	Edgar Link	pending
a123120ex-102077.jpg	Edgar Link	pending
a123120ex-102078.jpg	Edgar Link	pending
a123120ex-102079.jpg	Edgar Link	pending
a123120ex-102080.jpg	Edgar Link	pending
a123120ex-102081.jpg	Edgar Link	pending
a123120ex-102082.jpg	Edgar Link	pending
a123120ex-102083.jpg	Edgar Link	pending
a123120ex-102084.jpg	Edgar Link	pending
a123120ex-102085.jpg	Edgar Link	pending
a123120ex-141.htm	Edgar Link	pending
a123120ex-141001.jpg	Edgar Link	pending
a123120ex-141002.jpg	Edgar Link	pending
a123120ex-141003.jpg	Edgar Link	pending
a123120ex-141004.jpg	Edgar Link	pending
a123120ex-141005.jpg	Edgar Link	pending
a123120ex-141006.jpg	Edgar Link	pending
a123120ex-141007.jpg	Edgar Link	pending
a123120ex-141008.jpg	Edgar Link	pending
a123120ex-141009.jpg	Edgar Link	pending
a123120ex-141010.jpg	Edgar Link	pending
a123120ex-141011.jpg	Edgar Link	pending
a123120ex-141012.jpg	Edgar Link	pending
a123120ex-141013.jpg	Edgar Link	pending
a123120ex-141014.jpg	Edgar Link	pending
a123120ex-141015.jpg	Edgar Link	pending
a123120ex-141016.jpg	Edgar Link	pending
a123120ex-141017.jpg	Edgar Link	pending
a123120ex-141018.jpg	Edgar Link	pending
a123120ex-141019.jpg	Edgar Link	pending
a123120ex-141020.jpg	Edgar Link	pending
a123120ex-141021.jpg	Edgar Link	pending
a123120ex-141022.jpg	Edgar Link	pending
a123120ex-141023.jpg	Edgar Link	pending
a123120ex-141024.jpg	Edgar Link	pending
a123120ex-141025.jpg	Edgar Link	pending
a123120ex-141026.jpg	Edgar Link	pending
a123120ex-141027.jpg	Edgar Link	pending
a123120ex-141028.jpg	Edgar Link	pending
a123120ex-211.htm	Edgar Link	pending
a123120ex-231.htm	Edgar Link	pending
a123120ex-311.htm	Edgar Link	pending
a123120ex-312.htm	Edgar Link	pending
a123120ex-321.htm	Edgar Link	pending
a123120ex-322.htm	Edgar Link	pending
avdl-20201231.htm	Edgar Link	pending
avdl-20201231.xsd	Edgar Link	pending
avdl-20201231_cal.xml	Edgar Link	unprocessable
avdl-20201231_def.xml	Edgar Link	unprocessable
avdl-20201231_g1.gif	Edgar Link	pending
avdl-20201231_htm.xml	Edgar Link	completed
avdl-20201231_lab.xml	Edgar Link	unprocessable
avdl-20201231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R100.htm	Edgar Link	pending
R101.htm	Edgar Link	pending
R102.htm	Edgar Link	pending
R103.htm	Edgar Link	pending
R104.htm	Edgar Link	pending
R105.htm	Edgar Link	pending
R106.htm	Edgar Link	pending
R107.htm	Edgar Link	pending
R108.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
R94.htm	Edgar Link	pending
R95.htm	Edgar Link	pending
R96.htm	Edgar Link	pending
R97.htm	Edgar Link	pending
R98.htm	Edgar Link	pending
R99.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AVDL
AVADEL PHARMACEUTICALS PLC Stock $avdl

2020 Q4 Form 10-K Financial Statement

#000101247721000004 Filed on March 09, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AVDL AVADEL PHARMACEUTICALS PLC Stock $avdl

2020 Q4 Form 10-K Financial Statement

#000101247721000004 Filed on March 09, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AVDL
AVADEL PHARMACEUTICALS PLC Stock $avdl